Chemistry and Industry

View more issues:

Articles in Feb 23, 2009 issue of Chemistry and Industry

• Q4 collapse for US chemical sales
  by Neil Eisberg
• Dow Corning
  by Mark Whitfield
• Human cloning failure
• Schering-Plough
  by Neil Eisberg
• Metal Ions in Biological Sytems, vol. 35
  by Reginald Prince
• No GM oilseed rape in EU
• Allegra centrifuges
• Rheometer range
• Zero dead space valve
• Diode array systems
• Solvent removal
• Benchtop centrifuge
• The chemical tanker Ece, which was severely damaged following a collision with a bulk carrier has sunk in the English Channel
  by Mark Whitfield
• Multiple-sample purification
• Permeability measurements
• In a carbon dioxide-busting effort that is providing comics on the US West Coast with more material than they could have dreamt of, Lloyd Levine, a Californian assemblyman, wants his state to be the first to ban incandescent light bulbs
  by Mark Whitfield
• Inside India: India's buoyant chemicals industry is enjoying exceptional growth as the nation speeds towards becoming the world's second largest economy by 2050
  by Mark Whilfield
• Merck Group
  by Neil Eisberg
• Akzo Nobel 2004 sales
• Diamond for pure sound: less distortion at high frequencies
  by Marina Murphy
• Flangeless fittings
• Morphosys
  by Mark Whitfield
• Unclear future for Sanofi-Aventis
  by Emma Dorey
• Filter efficiency test
• Organic synthesis revisited
  by Laurence Harwood
• Akzo Nobel spin-off
• Syngenta notches up $8bn sales for first time
  by Patrick Walter
• Organometallic chemistry
  by Kevin Burgess
• Organic chemistry
  by G. Richard Stephenson
• Organometallic chemistry
  by Kevin Burgess
• The emergence of life: from chemical origins to synthetic biology
  by Alastair Strain
• The chemistry of polymers
  by David Sherrington
• Bio Base Europe, the result of a partnership between Belgium's Ghent Bio-Energy Valley and Biopark Terneuzen in the Netherlands, has been granted 21m [euro] of funding from the EU, Flanders in Belgium and the Dutch government under the framework of an Int
• GM groups claim 2008 successes
  by Andrew Turley
• Organic chemistry
  by G. Richard Stephenson
• Swiss allosteric modulation company Addex Pharmaceuticals has signed a second collaboration within a month with US pharma major Merck & Co, in this case, for the development of a new schizophrenia drug ADX63365, which is a positive allosteric modulato
• Diary
• Confidence leads to high share price
  by Robert Winder
• Ciba shrugs off $200m loss
  by Sean Milmo
• Diary
• Dutch chemical major Akzo Nobel has restated its financial results for the first three quarters of 2008 consolidating the performance of National Starch, which had been listed as a discontinued operation due to its expected sale that did not take place
  by Neil Eisberg
• Industry backs 'Factory Watch' initiative
• ICI confident as O'Neill takes the helm
• Quenching the world's thirst
  by James D. Birkett
• Confronting the epidemic of hepatitis B and C
  by Mark A. Feitelson
• A Devotion to Their Science: Pioneer Women of Radioactivity
  by Catherine J. Didion
• Navigating Change: How CEOs, Top Teams and Boards Steer Transformation
  by Mike Woods
• Cutting the cost of information
  by Rick Johnson
• Cancer survival on increase
• HRT cancer recurrence risk unacceptable
• Europeans on Mars
• Novartis: white knight for Aventis?
  by Cath O'Driscoll
• New super-heavies created by US-Russian collaboration
  by Marina Murphy
• Avian flu infection reaches an unprecedented scale
  by Cath O'Driscoll
• Health food industry challenges EU Food Supplements Directive
  by Cath O'Driscoll
• Biggest carbon storage project under way
  by Marina Murphy
• Efficient nitrogen fix found for fertilisers
  by Cath O'Driscoll
• Tower of power to go ahead
• Pill promise to solve premature ejaculation
  by Marina Murphy
• Rich pickings for pharmaceuticals: increased sales boosted pharmaceutical companies' profits at the end of 2003, but the outlook for 2004 is mixed
  by Cath O'Driscoll
• Squeeze on profits continues to bite as mixed fortunes beset chemicals sector; high raw material and energy costs continue to put pressure on profit margins in the chemicals sector, but some companies appear to be weathering the storm better than others.
  by Cath O'Driscoll
• Sars virus 'more easily infectious'
• Worm gene helps mice to produce fish oil
• On track for levitation of trains using condensate
• Planet Osiris surrounded by oxygen and carbon
• Alcohol could cut fuel cell costs
  by Cath O'Driscoll
• Leptin gene injection may combat obesity
  by Marina Murphy
• Primitive plastic pioneered by master da Vinci
• Global warming innovation without legislation work?
  by Robert Searles
• Internal buyouts: internal buyouts support the long-term drug-development strategies of pharma companies by creating flexible R&D resources and structures
  by Gunter Festel
• Informex: a hive of activity: Robert Winder continues the round-up of the stories making the news at the 20th Informex trade show in Las Vegas
  by Robert Winder
• Going for growth: Robert Winder reports on how market maturity is failing to slow growing demand for biocides
  by Robert Winder
• Food of the gods
  by Kevin Smith
• Science's top ten
  by John Emsley
• Inorganic chemistry
  by Timothy Hughbanks
• Analytical chemistry
  by Tom McCreedy
• Advanced materials
  by Arno Kraft
• Wyeth Pharmaceuticals
• KuDOS Pharmaceuticals
• Novagali Pharma

• 1
• 2
• 3
• 4
• 5
• 6